Literature DB >> 20630714

Anterior cingulum volumetry, auditory P300 in schizophrenia with negative symptoms.

Ulrich W Preuss1, Thomas Zetzsche, Oliver Pogarell, Christoph Mulert, Thomas Frodl, Dirk Müller, Gisela Schmidt, Christine Born, Maximilian Reiser, Hans-Jürgen Möller, Ulrich Hegerl, Eva M Meisenzahl.   

Abstract

The anterior cingulate cortex (ACC) is located at the rostum of the corpus callosum and involved in both cognitive and emotional brain processes. It has been suggested to be involved in P300 event-related potential generation. A large sample of schizophrenia inpatients and controls was examined in order to assess the potential relationship between ACC volumes and P300 characteristics in patients with more pronounced negative symptoms. In 50 male schizophrenia patients and 50 matched controls, auditory P300 and structural magnetic resonance imaging volume measurements of the ACC were obtained. Patients' negative symptoms were assessed using the PANSS (Positive and Negative Syndrome Scale). Volumetry of ACC subregions revealed a volume reduction in patients with schizophrenia compared with controls in right hemispheric rostral ACC subregions that were most pronounced in more negative schizophrenia patients. There was a positive correlation between PZ P300 amplitude and total ACC volume in the right hemisphere in schizophrenia patients with less negative symptoms. The results support the assumption that structural changes of the ACC are more pronounced in subgroups of schizophrenia patients with more negative psychopathology. In addition, while right hemisphere ACC volumes significantly differ between schizophrenia subgroups, combining measures of event-related potential (ERP) and ACC volumetry does not add additional information. Copyright 2010 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20630714     DOI: 10.1016/j.pscychresns.2010.05.008

Source DB:  PubMed          Journal:  Psychiatry Res        ISSN: 0165-1781            Impact factor:   3.222


  6 in total

1.  Effects of eye dominance (left vs. right) and cannabis use on intermanual coordination and negative symptoms in schizophrenia patients.

Authors:  Inge Gorynia; Markus Schwaiger; Andreas Heinz
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2014-05-04       Impact factor: 5.270

2.  Multivoxel proton MR spectroscopy used to distinguish anterior cingulate metabolic abnormalities in patients with schizophrenia.

Authors:  Caitlin J Hardy; Assaf Tal; James S Babb; Nissa N Perry; Julie W Messinger; Daniel Antonius; Dolores Malaspina; Oded Gonen
Journal:  Radiology       Date:  2011-09-07       Impact factor: 11.105

3.  Hypo-metabolism of the rostral anterior cingulate cortex associated with working memory impairment in 18 cases of schizophrenia.

Authors:  Robert Mazgaj; Assaf Tal; Raymond Goetz; Mariana Lazar; Karen Rothman; Julie Walsh Messinger; Dolores Malaspina; Oded Gonen
Journal:  Brain Imaging Behav       Date:  2016-03       Impact factor: 3.978

4.  Reduced anterior cingulate gray matter volume and thickness in subjects with deficit schizophrenia.

Authors:  Mizuho Takayanagi; Jacqueline Wentz; Yoichiro Takayanagi; David J Schretlen; Elvan Ceyhan; Lei Wang; Michio Suzuki; Akira Sawa; Patrick E Barta; J Tilak Ratnanather; Nicola G Cascella
Journal:  Schizophr Res       Date:  2013-09-12       Impact factor: 4.939

5.  Meta-analysis of structural and functional brain abnormalities in schizophrenia with persistent negative symptoms using activation likelihood estimation.

Authors:  Tingting Zhu; Zixu Wang; Chao Zhou; Xinyu Fang; Chengbing Huang; Chunming Xie; Honglin Ge; Zheng Yan; Xiangrong Zhang; Jiu Chen
Journal:  Front Psychiatry       Date:  2022-09-27       Impact factor: 5.435

6.  Ribosomal DNA transcription in the dorsal raphe nucleus is increased in residual but not in paranoid schizophrenia.

Authors:  Marta Krzyżanowska; Johann Steiner; Ralf Brisch; Christian Mawrin; Stefan Busse; Katharina Braun; Zbigniew Jankowski; Hans-Gert Bernstein; Bernhard Bogerts; Tomasz Gos
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2014-08-05       Impact factor: 5.270

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.